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Introduction. Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid. An accurate cytological diagnosis
is based on distinctive cytological features in combination with immunocytochemistry. Methods. A number of 83 ﬁne needle
aspirations, positive for papillary thyroid cancer (44 from thyroid nodules and 39 from cervical lymph nodes), were studied using
Thin Layer Cytology. A panel of the immunomarkers Cytokeratin-19, Galectin-3, HBME1, CD-44, CD-56, and E-Cadherin was
performed.Results.PositiveexpressionofCK-19wasobservedin77cases(92.7%),ofGalectin-3in74cases(89.1%),ofHBME1in
65 (78.3%), and of CD-44 in 72 cases (86.7%). Loss of expression of CD-56 was observed in 80 cases (96.4%) and of E-cadherin in
78 (93.9%). Conclusions. Our data suggest that Thin Layer Cytology increases the diagnostic accuracy in papillary carcinoma and
seems to be a promising technique for further investigation of thyroid lesions permitting the possibility to use archive material.
Positive immunoexpression of CK-19, Galectin-3, HBME-1, and CD-44 improves the diagnostic accuracy of papillary thyroid
cancer. Furthermore, loss of E-cadherin and of CD-56 expression is a feature of malignancy.
1.Introduction
Papillary thyroid carcinoma (PTC) is the most common
malignancy of the thyroid gland, and ﬁne needle aspiration
cytology (FNAC) is the only preoperative diagnostic method
used in its detection. The cytological diagnosis of PTC is
considered particularly reliable and allows for a deﬁnitive
diagnosis and treatment planning at the time of FNA [1, 2]
as it is based on speciﬁc cytomorphological characteristics.
However, these characteristics can occur in other thyroid
lesions, both benign and malignant. In such cases, immuno-
cytochemistry seems to play an important role in order to
facilitate the uncertain results and helps to avoid diagnostic
pitfalls.
Although FNAC is widely accepted as the primary diag-
nostic procedure for thyroid nodules [1], few reports have
been published regarding immunocytochemistry mainly on
liquid-based Thin Layer technique [3]. According to recent
research, several diagnostic and prognostic markers have
been proposed in improving the diagnostic accuracy of
papillary thyroid cancer such as Cytokeratin-19 (CK-19),
HBME-1, Galectin-3, CD44, CD56, E-cadherin, c-erbB-2,
p21cip1,p 2 7 kip1, and p16ink4a [4–13]
Thepurpose ofourstudywastheevaluationofimmuno-
chemistry in combination with cytomorphology in the
diagnosis of papillary cancer in FNA smears using liquid-
based cytology.
2.MaterialsandMethods
Cytopathological ﬁles of primary papillary thyroid cancer as
well as metastatic ones were reviewed from our cases during
the last ﬁve years. A total number of 83 FNA cases were
included; 44 were from thyroid nodules and 39 from cervical
lymph nodes. In addition, 30 benign cases that belonged2 Journal of Oncology
mainly in thyroid adenomatous nodules were used as con-
trol. The majority of the cases concerned ultrasound-guided
aspirations of thyroid nodules or lymph nodes performed
in collaboration with an experienced endocrinologist and
cytopathologistonsite.Allmalignantcasesandcontrolswere
histologically conﬁrmed.
The cytological material was prepared using, mainly,
liquid-based cytology. The conventional method was used
in 13 cases. Immediately after the aspiration, one or two
conventional smears were prepared, and the remaining
sample was rinsed immediately in a Preservcyt (Cytyc
Corporation, Boxborough, MA). A thin evenly dispersed
monolayer of cells was dispersed from the ﬁlter onto the
slide in a cycle of 20mm in diameter. ThinPrep slides were
preparedinthelaboratoryusingtheTP2000instrument,and
both conventional and ThinPrep slides were stained with a
modiﬁed Papanicolaou method. Immunocytochemistry was
performed only in slides prepared by thin layer method.
All samples were stained in an automated immunostainer
(Ventana ES, Ventana medical system, Inc., Tucson, AZ,
USA) and the related Ventana reagents were used, using
standard manufacturer’s instructions. Our panel included
Cytokeratin 19 (Dilution 1:50, Clone b170, IgG-1, Ylem),
Galectin-3(Dilution1:50,Clone9C4,Novocastra),HBME-1
(Dilution 1:50,monoclonal HBME,Ylem),CD44 (Dilution
1:50, Clone DF1485, IgG1, Dako), CD-56 (Dilution 1:50,
Clone Moc-1, Dako), and E-cadherin (Dilution 1:25, Clone
36B5, Novocastra).
According to manufacturer’s suggestions, the samples
were immersed in a citrate buﬀe rs o l u t i o na n dh e a t e df o r
20 minutes at 350W. The slides were rinsed in tap water
for 5 minutes, and then they were incubated with 3%
H2O2 for 4 minutes to quench the endogenous peroxidase
activity. We used the primary antibodies diluted in an
appropriate dilution with Ventana antibody diluent in a
Venatana user ﬁllable dispenser. A standard avidin-biotin
method was applied. The primary antibody was bound by
a biotin-conjugated mouse secretory antibody formulation
and next an avidin enzyme conjugate bound to the biotin
present on the secondary antibody followed. The primary
antibody-secondary antibody-avidin enzyme complex was
then visualized utilizing a precipitating enzyme product. The
staining intensity was assessed in a semiquantitative way,
independently by two experienced cytopathologists. A scale
f r o mn e g a t i v e( 0 )t ow e a k( 1 ) ,m o d e r a t e( 2 ) ,a n ds t r o n g
(3) was applied to each slide while the pattern of stain was
classiﬁed as membranous or cytoplasmic, diﬀuse or nuclear.
A positive stain was deﬁned by the presence of either a
moderate (2) or a strong stain (3) in at least 10% of tumor
cells, and the percentage of the remaining positive cells, was
evaluated.
3.StatisticalAnalysis
A standard independent-samples t-test was used for the
evaluation of diﬀerences in the expression between each
immunomarkerincancermaterialandcontrols,respectively.
Calculations were carried out using SPSS version 14.0.
Figure 1: Papillary thyroid carcinoma (left) and normal thyroid
tissue (right) (Pap stain ×400).
Figure 2: CK-19 expression in a PTC case (left) and negative
normal control (right) (ThinPrep ×400).
Results were considered statistically signiﬁcant when P-value
was less than .05.
4. Results
Our cases included 44 FNAs of thyroid nodules, diagnosed
as papillary thyroid cancers, and 39 FNAs from cervical
lymph nodes with metastases from papillary thyroid cancer
too (Figure 1). CK-19 was positive in 77 out of 83 cases
(92.7%), with strong diﬀuse membranous and cytoplasmic
staining (Figure 2). Galectin-3 was positive in 74 out
of 83 cases (89.1%) with a strong cytoplasmic immune
expression (Figure 3). HBME1 showed a predominantly
strong membranous pattern and was positive in 65 out
of 83 cases (78.3%) (Figure 4). CD-44 was positive in
72 out of 83 cases (86.7%), and the staining was intense
membranous and diﬀuse cytoplasmic (Figure 5). No sample
of the control group showed positivity in the above four
controlled immunomarkers (Table 1(a)).
A week positive stain to CD-56 was observed in 3 (3.6%)
cases, while 80 (96.4%) cases showed loss of expression.
E-cadherin was positive in 5 out of 83 (6%) cases, andJournal of Oncology 3
Table 1
(a) Results of Immunocytochemistry in FNAs, cases, and controls, (n is the number of samples)
Cases Cases Controls
Immunomarker Expression Loss of expression P Expression
n % n % n %
CK-19 77 92.7 6 7.3 <.005 — —
Galectin-3 74 89.1 9 10.9 <.005 — —
HBME1 65 78.3 18 21.7 <.005 — —
CD-44 72 86.7 11 13.3 <.005 — —
(b) Expression of CD-56 and E-Cadherin in FNAs, cases, and controls. n is the number of samples
Cases Cases Controls
Immunomarker Expression Loss of expression P Expression
n % n % n %
CD-56 3 3.6 80 96.4 <.005 30 100
E-Cadherin 5 6.0 78 94.0 <.005 30 100
Figure 3: Galectin-3 expression in a PTC case (left) (×400) and
negative normal control (right).
78 (93.97%) cases showed loss of expression. All controls
retained their normal expression in the above two immuno-
markers (Table 1(b)).
The immunoexpression of all markers was similar in
both thyroid and lymph node FNAs. The microscopic
evaluationofeachimmunomarkerexpressionissummarized
in Tables I(a) and I(b) and Figure 6.
5. Discussion
It is well known that FNA is usually the ﬁrst choice for
the preoperative diagnostic evaluation of thyroid nodules
in everyday clinical practice [1, 2]. A preoperative accurate
diagnosis of papillary thyroid cancer is important in deter-
mining the clinical management of these patients. Acquiring
a good aspirate is the ﬁrst step toward a correct diagnosis.
The preoperative diagnosis of PTC with FNAc does not
present diﬃculties, as PTC presents distinctive features
including nuclear grooves, papillary fronds, monolayered
sheets of cells, psammoma bodies, multinucleate giant cells,
Figure 4: HBME-1 expression in a PTC case (×400).
and intranuclear cytoplasmic inclusions. However, these
cytomorphologic criteria are not always possible to observe.
Furthermore, follicular and papillary patterns are often
overlappingbetweenbenignandmalignantlesions.Forthese
reasons, diagnostic pitfalls may be noted [14]. Based on
our experience and according to the literature data, the
follicular variant of papillary carcinoma is thought to be
one of the most common causes of false negative cytologic
diagnosis of PTC [15]. On the other hand, occult and cystic
papillary carcinoma may be a source of error. Therefore,
the distinction of true papillary thyroid carcinoma from
lesions that share some cytologic features with PTC is of
clinical importance. We suggest that immunocytochemistry
can play an important role in the diﬀerential diagnosis of
these uncertain or borderline cases [4, 9, 15].
In this study, we found that CK-19, Galectin-3, CD-44,
and HBME1 were highly expressed in papillary carcinomas,
a ﬁnding that is in agreement with other data reported in
the literature [5, 8, 10, 16–19]. Moreover, we demonstrated
that the immunoexpression of CD-56 and E-cadherin was
absentinalmostallcasesofthisstudyandthiscoincideswith
literature data.4 Journal of Oncology
Figure 5: CD-44 expression in a PTC case (×100).
ItisreportedthatCK-19,acytoskeletalprotein,issigniﬁ-
cantlyincreasedinpapillarythyroidcarcinomaandishelpful
in distinguishing papillary thyroid cancer from benign or
other malignant thyroid carcinomas [4]. A strong diﬀuse or
membranous immunoexpression stain, as we have found in
our cases, is considered to be in favor of PTC, but focal CK19
staining may be found in benign lesions as well. Galectin-3 is
a glucoprotein that plays an important role in organogenesis.
It belongs to the family of lectins, is localized mainly in
the cytoplasm, and is involved in regulating cell-cell and
cell-matrix interactions. Galectin-3 staining is considered
positive when cytoplasmic membranous or nuclear staining
is present. Many series, as well as the present study, have
showed that Galectin-3 is useful as a marker of malignancy
in thyroid nodules although some studies have produced
conﬂictive results [20]. The standard form of CD-44, an
adhesion molecule, has been associated with extracellular
matrix adhesion and lymphocyte homing. Variable expres-
sion of CD-44in PTCs has been demonstrated, and these
carcinomas were found to express intense cell membrane or
diﬀuse cytoplasmic staining. CD-44 was expressed in 86.7%
of our cases, and the staining was intense membranous and
diﬀuse cytoplasmic. HBME1 is a marker of mesothelial cells
and is expressed in malignant thyroid follicular tumors. It
is recently applied as an immunomarker in PTCs with high
expression. However, this positive immunoexpression does
not exclusively indicate papillary diﬀerentiation [21]. Our
results showed that HBME1 is expressed in a high percentage
of PTCs cases.
CD-56, a neural cell adhesion molecule, is present in
follicular epithelial cells of normal thyroid. The expression
of CD-56 protein was found to be strong within all nonma-
lignant thyroid cells, but not in cases of PTCs [5]. 96.4%
of our cases with PTC showed loss of its expression. On
the contrary, all our controls expressed CD-56. E-cadherin,
a 120-Kda glucoprotein with a transmembrane domain,
is a calcium-dependent homophilic cell adhesion molecule
which plays a central role in epithelial integrity, in cell
adhesion anddiﬀerentiation, as wellas in the maintenance of
cellpolarityandtissuearchitecture.Itsimpairmentcorrelates
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Figure 6: Schematic presentation of the expression of each of the
six immunomarkers in our 83 cases. Positive means cases with
expression of the immunomarker. Negative means cases with no
expression or loss of expression, (in the case of CD-56 and E-
Cadherin).
with tumor invasion and metastasis [22]. 94% of the cases
in this study showed loss of the expression of E-cadherin
and all control aspirates expressed it. We suggest that loss
of expression of CD-56 and E-cadherin may provide an
objective diagnostic tool, and they may be extremely useful
in the diagnosis of PTCs, especially in equivocal cases.
Cytologic material used by the conventional method
is in most cases unavailable for additional investigation
either due to the inadequacy of cellularity or the presence
of excess blood mucus or inﬂammation. This gap is ﬁlled
by liquid-based cytology and thin layer techniques which
may be eﬀective innovations [23]. The quality of the
immunocytochemical reaction on the thin layer prepared
slides as far as the morphologic details, and the purity of
background is considered to be better than conventional
smears. Liquid-based cytology oﬀers the possibility of cre-
ating archival material and applying new techniques, such
as immunocytochemistry in the same sample, and this is
signiﬁcant for further and future revaluation. The gold
standard of immunocytochemistry, in order to lead to an
accurate diagnosis, is the use of a panel with at least two
or three markers in combination with cytomorphology [17,
24]. Attention should be made to the extent, intensity, and
pattern of staining. Liquid-based cytology has been validated
extensively for the preoperative diagnosis of thyroid nodules
[23, 24]. This method is fully reproducible, performed
by minimum training of personnel, is safe, time eﬀective,
and oﬀers the possibility of an accurate application of
immmunocytochemistry for the study of neoplastic thyroid
lesions. To our knowledge, immunocytochemistry in the
diagnosis of papillary thyroid cancer in FNA’s using liquid-
based cytology is for the ﬁrst time used in such an extensive
material.
6. Conclusions
Our results suggest the following. (1) A precise diagnosis
of PTC in ﬁne needle aspiration material is practicableJournal of Oncology 5
and credible with the use of contemporary liquid cytology
techniques and immunocytochemistry, which is the key for a
correct and accurate diagnosis. (2) Positive immunoexpres-
sion of CK-19, Galectin-3, CD-44, and HBME1 contributes
the most in PTCs diagnosis, and these antibodies can be
considered as ﬁrst-line immunomarkers. Although HBME1
is not necessarily a marker of papillary diﬀerentiation,
it serves as an indicator of thyroid papillary malignancy
especiallyincombinationwiththeabovemarkers.(3)CD-56
can assist in decision making about the benign or malignant
nature of the aspirated material. Loss of expression seems to
agree with the presence of papillary thyroid cancer. (4) Loss
of the expression of E-cadherin seems to serve as a good
indicative marker of malignancy. (5) Thin layer cytology
is a promising technique for the investigation of thyroid
lesions and increasing the diagnostic accuracy in papillary
carcinoma. (6) There is a clear need for the development
of additional molecular markers in order to improve the
diagnostic capabilities and thereby advance the clinical
management in patients with borderline FNA results.
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